New Pre-Clinical Data on a vTv Therapeutics Small Molecule Drug Candidate Against Parkinson’s Disease to be Presented at th...
November 16 2016 - 9:03AM
Business Wire
vTv Therapeutics Inc. (vTv, Nasdaq:VTVT), a clinical-stage
biopharmaceutical company engaged in the discovery and development
of new orally administered small molecule drug candidates to fill
significant unmet medical needs, today announced that Dr. Bobby
Thomas, Associate Professor at Medical College of Georgia, Georgia
Regents University at Augusta, will present a poster at the Society
for Neuroscience 2016 meeting in San Diego, featuring new
pre-clinical data on a vTv small molecule drug candidate against
Parkinson’s disease (PD).
vTv has identified novel non-electrophilic Nrf2/Bach1 modulators
that can activate nuclear factor-E2 related factor (“Nrf2”) and
inhibit Bach1 (the Antioxidant Response Element (“ARE”)
transcriptional repressor) leading to potent activation of the Nrf2
pathway. The results from the laboratory of Dr. Thomas suggest (1)
Bach1 may be a promising novel target for drug development against
Parkinson's disease, and (2) vTv's compound, HPPE, may protect
against nigrostriatal dopaminergic neurodegeneration by virtue of
its ability to activate neuroprotective Nrf2/ARE genetic response
in a preclinical mouse model of Parkinson's disease.
Based on recent findings, aberrant oxidative stress and
inflammation play a key role in the pathogenesis of PD and
preclinical studies suggest that activating the Nrf2/Bach1 pathway
could have disease modifying effects on PD. Current pharmacological
approaches targeting the Nrf2 pathway presents safety and
tolerability issues as these pharmacophores contain reactive
electrophilic groups.
Parkinson's disease is a progressive and debilitating
neurodegenerative movement disorder characterized by marked
nigrostriatal dopaminergic cell loss in the brain. No preventive
therapy or cure is yet available for PD.
Dr. Thomas will be available to discuss the findings at the
Society for Neuroscience 2016 meeting on Wednesday Nov. 16 from
1-5:00 pm at poster #19, Hall D-H at San Diego Convention
Center.
About vTv Therapeutics
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical
company engaged in the discovery and development of orally
administered small molecule drug candidates to fill significant
unmet medical needs. vTv has a pipeline of clinical drug candidates
led by programs for the treatment of Alzheimer’s disease and type 2
diabetes as well as treatment of inflammatory disorders and the
prevention of muscle weakness.
The company's Alzheimer’s disease drug
candidate, azeliragon, is a novel oral small molecule
antagonist of the Receptor for Advance Glycation Endproducts (RAGE)
with first-in-class potential.
The azeliragon development program has been granted Fast
Track Designation and agreement on its Phase 3 protocol has been
reached with FDA via a Special Protocol Assessment (SPA).
Enrollment of part A of the Phase 3 STEADFAST study in patients
with mild Alzheimer's disease was completed during the third
quarter and topline data from this part of the study is anticipated
to be reported in early 2018.
vTv is also pursuing the clinical development of
TTP399, a novel liver selective Glucokinase Activator (GKA) with
first-in-class potential for the treatment of type 2 diabetes. The
company recently announced positive top line results from the six
month phase 2b AGATA Study in subjects with type 2 diabetes.
vTv’s second diabetes drug candidate, TTP273, is an oral, small
molecule GLP-1R agonist with best-in-class potential. The company
reported the completion of enrollment of the three month Phase 2
LOGRA study in the third quarter with data readout expected at the
end of 2016. The previous Phase 1b trial of TTP273 demonstrated
robust effects on postprandial and fasting glucose. All doses of
TTP273 were well tolerated with no serious adverse events or
evidence of gastrointestinal side effects compared to placebo.
Forward-Looking Statements
This release contains forward-looking statements, which involve
risks and uncertainties. These forward-looking statements can be
identified by the use of forward-looking terminology, including the
terms “anticipate,” “believe,” “could,” “estimate,” “expect,”
“intend,” “may,” “plan,” “potential,” “predict,” “project,”
“should,” “target,” “will,” “would” and, in each case, their
negative or other various or comparable terminology. All statements
other than statements of historical facts contained in this
release, including statements regarding the timing of our clinical
trials, our strategy, future operations, future financial position,
future revenue, projected costs, prospects, plans, objectives of
management and expected market growth are forward-looking
statements. These statements involve known and unknown risks,
uncertainties and other important factors that may cause our actual
results, performance or achievements to be materially different
from any future results, performance or achievements expressed or
implied by the forward-looking statements. Important factors that
could cause our results to vary from expectations include those
described under the heading “Risk Factors” in our Annual Report on
Form 10-K and our other filings with the SEC. These forward-looking
statements reflect our views with respect to future events as of
the date of this release and are based on assumptions and subject
to risks and uncertainties. Given these uncertainties, you should
not place undue reliance on these forward-looking statements. These
forward-looking statements represent our estimates and assumptions
only as of the date of this release and, except as required by law,
we undertake no obligation to update or review publicly any
forward-looking statements, whether as a result of new information,
future events or otherwise after the date of this release. We
anticipate that subsequent events and developments will cause our
views to change. Our forward-looking statements do not reflect the
potential impact of any future acquisitions, merger, dispositions,
joint ventures or investments we may undertake. We qualify all of
our forward-looking statements by these cautionary statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161116005900/en/
vTv
TherapeuticsInvestorsIR@vtvtherapeutics.comorMediaNura
Strong, 336-841-0300 X164PR@vtvtherapeutics.com
vTv Therapeutics (NASDAQ:VTVT)
Historical Stock Chart
From Aug 2024 to Sep 2024
vTv Therapeutics (NASDAQ:VTVT)
Historical Stock Chart
From Sep 2023 to Sep 2024